Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) have been assigned an average rating of “Hold” from the six brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $6.00.
Several analysts recently commented on NBY shares. Zacks Investment Research raised shares of NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 6th. HC Wainwright set a $4.00 target price on shares of NovaBay Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 8th.
Shares of NovaBay Pharmaceuticals stock traded down $0.15 on Friday, hitting $1.91. The stock had a trading volume of 15,746 shares, compared to its average volume of 12,836. NovaBay Pharmaceuticals has a twelve month low of $1.25 and a twelve month high of $4.80.
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Featured Article: How are the companies in the S&P 500 selected?
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.